Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[ 18F]levodopa positron emission tomography in patients with Parkinson's disease

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 1, 2001, Pages 33-41

  Dietz, M ^a,b,c,d   Harder, S ^a,b,c,d   Graff, J ^a,b,c,d   Kunig G ^a,b,c,d   Vontobel, P ^a,b,c,d   Leenders, K L ^a,b,c,d   Baas, H ^a,b,c,d  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Clinic for Neurology and Neurogeriatry   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORINE 18 LEVODOPA; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUORINE 18; LEVODOPA; MOCLOBEMIDE; PHENOTHIAZINE DERIVATIVE; RESERPINE; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DISEASE MODEL; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; STATISTICAL MODEL; TISSUE DISTRIBUTION;

ADULT; AGED; ANTIPARKINSON AGENTS; CAUDATE NUCLEUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE AGENTS; FEMALE; FLUORINE RADIOISOTOPES; HALF-LIFE; HUMANS; LEVODOPA; LINEAR MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034921957     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.116328     Document Type: Article

References (37)

1. New developments in the pathology of Parkinson's disease
2. Levodopa in the treatment of Parkinson's disease: A consensus meeting
3. Is dopamine formed from exogenous L-dopa stored within vesicles in striatal dopaminergic nerve terminals?
4. Basic mechanisms of motor fluctuations
5. Concentration/effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation
6. Pharmacodynamics of levodopa coadministered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations
7. Concentration-response relationship of levodopa in patients at different stages of PD
8. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release in parkinsonian patients
9. Pharmacodynamic modeling of oral levodopa
10. A levodopa kinetic-dynamic study of the rate of progression in PD
11. Concentration-effect relationship of levodopa in patients with Parkinson's disease
12. 18F-L-dopa
13. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
14. Pathophysiology of movement disorders studied using PET
15. 18F]-fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography
16. 18F-fluoro-L3,4-dihydroxy-phenylalanine in the primate
17. Accuracy of clinical diagnosis of idiopathic PD: A clinico-pathological study of 100 cases
18. Qualitative assessment of Parkinson's disease: Study of reliability and data reduction with an abbreviated Columbia scale
19. Value and appropriate use of rating scales and apparative measurements in quantification of disability in PD
20. Simple and rapid micromethod for the determination of levodopa and 3-0-methyldopa in human plasma by HPLC with colorimetric detection
21. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
22. Complementary positron emission tomographic studies of the striatal dopaminergic system in PD
23. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease
24. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations
25. Parkinsonism: Onset, progression and mortality
26. 6-[18F]fluoro-L-DOPA metabolism in living human brain: A comparison of six analytical methods
27. Measuring the rate of progression and estimating the preclinical period of PD with [18F]dopa PET
28. 18F]fluorodopa: Implications for compartmental modelling and clinical usefulness
29. Fetal tissue transplantation [correction of transplantation] in Parkinson's disease
30. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease
31. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study
32. PET studies of the striatal dopaminergic system in PD
33. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological, and neurochemical correlations
34. [3H]Spiperone binding, dopamine and HVA concentration in PD, multiple system atrophy, and progressive nuclear palsy
35. Biochemical pathophysiology of PD
36. The evolution and origin of motor complications in Parkinson's disease
37. Pharmacokinetic-pharmacodynamic relationship of levodopa under tolcapone in patients with Parkinson's disease